Cargando…

Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases

Renal fibrosis is the inevitable common end-point of all progressive chronic kidney diseases. The underlying mechanisms of renal fibrosis are complex, and currently there is no effective therapy against renal fibrosis. Renal microvascular rarefaction contributes to the progression of renal fibrosis;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Changxiu, Zhu, Xiaoyu, Wei, Xuejiao, Long, Mengtuan, Jiang, Lili, Li, Chenhao, Jin, Die, Du, Yujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	State-of-the-Art Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154791/ https://www.ncbi.nlm.nih.gov/pubmed/35618410 http://dx.doi.org/10.1080/0886022X.2022.2079528

Ejemplares similares

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Metabolic Reprogramming and Renal Fibrosis
por: Zhu, Xiaoyu, et al.
Publicado: (2021)

Targeting Vascular Calcification in Chronic Kidney Disease
por: Nelson, Adam J., et al.
Publicado: (2020)

Radiation-Induced Endothelial Vascular Injury: A Review of Possible Mechanisms
por: Venkatesulu, Bhanu Prasad, et al.
Publicado: (2018)

Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?
por: Ravona-Springer, Ramit, et al.
Publicado: (2003)

The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story
por: Nightingale, T, et al.
Publicado: (2013)

Molecular mechanisms underlying the role of hypoxia-inducible factor-1 α in metabolic reprogramming in renal fibrosis
por: Wei, Xuejiao, et al.
Publicado: (2022)

Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication
por: Kim, Jin Sug, et al.
Publicado: (2021)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Effect of magnesium on vascular calcification in chronic kidney disease patients: a systematic review and meta-analysis
por: Zhan, Ya, et al.
Publicado: (2023)

Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney
por: Simeoni, Mariadelina, et al.
Publicado: (2017)

Estrogen and estrogen receptors in kidney diseases
por: Ma, Hao-Yang, et al.
Publicado: (2021)

Anti-SARS-CoV-2 vaccine-induced myocarditis – real but, in general, rare and mild: A consensus statement from the Studies Committee of the Portuguese Society of Cardiology
por: Sousa, José Pedro, et al.
Publicado: (2023)

Iron metabolism-related indicators as predictors of the incidence of acute kidney injury after cardiac surgery: a meta-analysis
por: Zhao, Limei, et al.
Publicado: (2023)

Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease
por: Wang, Miao, et al.
Publicado: (2022)

Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention
por: Liu, Xuyan, et al.
Publicado: (2022)

Generation and Application of Directly Reprogrammed Endothelial Cells
por: Jung, Cholomi, et al.
Publicado: (2022)

Functional non‐coding RNAs in vascular diseases
por: Ono, Koh, et al.
Publicado: (2021)

Acute toxic kidney injury
por: Petejova, Nadezda, et al.
Publicado: (2019)

Genetic syndromes with vascular malformations – update on molecular background and diagnostics
por: Ustaszewski, Adam, et al.
Publicado: (2020)

HIV, Combination Antiretroviral Therapy, and Vascular Diseases in Men and Women
por: Kovacs, Laszlo, et al.
Publicado: (2022)

Advance of autophagy in chronic kidney diseases
por: Deng, Xu, et al.
Publicado: (2017)

Hyperuricemia, the heart, and the kidneys – to treat or not to treat?
por: Petreski, Tadej, et al.
Publicado: (2020)

Endothelial- and Immune Cell-Derived Extracellular Vesicles in the Regulation of Cardiovascular Health and Disease
por: Jansen, Felix, et al.
Publicado: (2017)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
por: Michos, Erin D., et al.
Publicado: (2023)

Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes
por: Münzel, Thomas, et al.
Publicado: (2020)

Therapeutic apheresis in kidney diseases: an updated review
por: Chen, Yi-Yuan, et al.
Publicado: (2022)

The role of kidney injury biomarkers in COVID-19
por: Su, Lianjiu, et al.
Publicado: (2022)

Pioglitazone in diabetic kidney disease: forgotten but not gone
por: Papaetis, Georgios S.
Publicado: (2022)

Advances in imaging techniques to assess kidney fibrosis
por: Jiang, Buchun, et al.
Publicado: (2023)

Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders
por: Packer, Milton
Publicado: (2020)

The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
por: Pokrywka, Andrzej, et al.
Publicado: (2015)

Lipids, blood pressure, kidney – what was new in 2011?
por: Barylski, Marcin, et al.
Publicado: (2011)

Biomarker for early renal microvascular and diabetic kidney diseases
por: Futrakul, Narisa, et al.
Publicado: (2017)

A long journey for acute kidney injury biomarkers
por: Oh, Dong-Jin
Publicado: (2020)

The research status and prospect of Periostin in chronic kidney disease
por: Jia, Yuan-yuan, et al.
Publicado: (2020)

Emergent processes in cognitive-emotional interactions
por: Pessoa, Luiz
Publicado: (2010)

Bipolar disorder
por: Goodwin, Frederick K., et al.
Publicado: (1999)

Depression in late life
por: Barry, D. Lebowitz
Publicado: (1999)

The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis
por: Davidson, Michael, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_nda757itak8bhf33iepr5i7nth